Summary
Global Markets Direct’s, ‘Bayer AG - Product Pipeline Review - 2016’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
- The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bayer AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bayer AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bayer AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bayer AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bayer AG Snapshot 7
Bayer AG Overview 7
Key Information 7
Key Facts 7
Bayer AG - Research and Development Overview 8
Key Therapeutic Areas 8
Bayer AG - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Pipeline Products - Partnered Products 18
Pipeline Products - Out-Licensed Products 20
Bayer AG - Pipeline Products Glance 22
Bayer AG - Late Stage Pipeline Products 22
Bayer AG - Clinical Stage Pipeline Products 25
Bayer AG - Early Stage Pipeline Products 30
Bayer AG - Unknown Stage Pipeline Products 33
Bayer AG - Drug Profiles 34
aflibercept 34
dienogest 37
Kovaltry 38
(candesartan cilexetil + nifedipine) 40
amikacin sulfate 41
ciprofloxacin hydrochloride 43
copanlisib hydrochloride 45
damoctocog alfa pegol 49
finerenone 50
nifurtimox 51
radium Ra 223 dichloride 52
regorafenib 55
rivaroxaban 59
tedizolid phosphate 65
(anastrozole + levonorgestrel) 68
anetumab ravtansine 69
BAY-1067197 71
BAY-1142524 72
molidustat 73
refametinib 75
riociguat 78
roniciclib 80
vericiguat 82
vilaprisan 83
sorafenib tosylate 84
BAY sGCstim 89
BAY-1082439 90
BAY-1093884 91
BAY-1112054 92
BAY-1125976 93
BAY-1128688 94
BAY-1129980 95
BAY-1143269 96
BAY-1143572 97
BAY-1161909 98
BAY-1163877 99
BAY-1179470 100
BAY-1187982 101
BAY-1213790 102
BAY-1214784 103
BAY-1217389 104
BAY-1251152 105
BAY-1862864 106
Drug for Diabetic Foot Ulcer 107
Monoclonal Antibodies for Oncology 108
Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers 109
Monoclonal Antibody for Undisclosed Indication 110
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis 111
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders 112
Small Molecule to Inhibit Kinase for Inflammation and Oncology 113
BAY sGCact 114
BAY-1001931 115
BAY-1024767 116
BAY-1436032 117
BAY-606583 118
Bay-846 119
Immunotherapy for Oncology 120
Monoclonal Antibodies for Undisclosed Indication 121
Monoclonal Antibody to Inhibit CGEN-15001T for Oncology 122
Monoclonal Antibody to Inhibit CGEN-15022 for Oncology 123
Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors 125
Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer 126
Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder 127
Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology 128
Small Molecules to Inhibit MTH1 for Oncology 129
Small Molecules to Inhibit Wnt Pathway for Oncology 130
SMYD-2BAY02 131
ZK-191784 132
ZK-216348 134
Drugs for Endometriosis and Uterine Fibroids 135
Recombinant Protein for Solid Tumors 136
Small Molecule to Inhibit Epigenetic Target for Oncology 137
Small Molecules for Cardiovascular Disease 138
Small Molecules for Oncology 139
Small Molecules to Inhibit GLUT1 and GLUT2 140
Small Molecule for Undisclosed Indication 141
Bayer AG - Pipeline Analysis 142
Bayer AG - Pipeline Products by Target 142
Bayer AG - Pipeline Products by Route of Administration 147
Bayer AG - Pipeline Products by Molecule Type 148
Bayer AG - Pipeline Products by Mechanism of Action 149
Bayer AG - Recent Pipeline Updates 153
Bayer AG - Dormant Projects 227
Bayer AG - Discontinued Pipeline Products 230
Discontinued Pipeline Product Profiles 230
Bayer AG - Locations And Subsidiaries 232
Head Office 232
Other Locations & Subsidiaries 232
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 243
Disclaimer 244
List of Tables
Bayer AG, Key Information 13
Bayer AG, Key Facts 13
Bayer AG - Pipeline by Indication, 2016 15
Bayer AG - Pipeline by Stage of Development, 2016 21
Bayer AG - Monotherapy Products in Pipeline, 2016 22
Bayer AG - Combination Treatment Modalities in Pipeline, 2016 23
Bayer AG - Partnered Products in Pipeline, 2016 24
Bayer AG - Partnered Products/ Combination Treatment Modalities, 2016 25
Bayer AG - Out-Licensed Products in Pipeline, 2016 26
Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 27
Bayer AG - Pre-Registration, 2016 28
Bayer AG - Phase III, 2016 29
Bayer AG - Phase II, 2016 31
Bayer AG - Phase I, 2016 33
Bayer AG - Preclinical, 2016 36
Bayer AG - Discovery, 2016 38
Bayer AG - Unknown, 2016 39
Bayer AG - Pipeline by Target, 2016 148
Bayer AG - Pipeline by Route of Administration, 2016 153
Bayer AG - Pipeline by Molecule Type, 2016 154
Bayer AG - Pipeline Products by Mechanism of Action, 2016 155
Bayer AG - Recent Pipeline Updates, 2016 159
Bayer AG - Dormant Developmental Projects,2016 233
Bayer AG - Discontinued Pipeline Products, 2016 236
Bayer AG, Subsidiaries 238
List of Figures
Bayer AG - Pipeline by Top 10 Indication, 2016 15
Bayer AG - Pipeline by Stage of Development, 2016 21
Bayer AG - Monotherapy Products in Pipeline, 2016 22
Bayer AG - Combination Treatment Modalities in Pipeline, 2016 23
Bayer AG - Partnered Products in Pipeline, 2016 24
Bayer AG - Out-Licensed Products in Pipeline, 2016 26
Bayer AG - Pipeline by Top 10 Target, 2016 148
Bayer AG - Pipeline by Top 10 Route of Administration, 2016 153
Bayer AG - Pipeline by Top 10 Molecule Type, 2016 154
Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2016 155
